{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE319nnn/GSE319733/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":[" Other","Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319733"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells","description":"The presence of B cells in tumors is correlated with a positive prognosis in several types of cancers, including high-grade serous ovarian cancer (HGSOC). These cells give rise to plasma cells (PCs) that originate from germinal centers (GCs) and secrete tumor-reactive antibodies. GCs also give rise to memory B cells (MBCs); yet, it is unknown if tumor-reactive MBCs form in cancer patients. Single-cell RNA-seq revealed that retroperitoneal lymph nodes (LNs) located near the tumor, host primarily class-switched resting MBCs. Immunoglobulin sequencing, clonal analysis, and generation of monoclonal antibodies demonstrated that these MBCs carried tumor-reactive antibodies, some of which bind MMP14, an enzyme abundantly expressed by HGSOC tumors. Although tumor-associated retroperitoneal LNs did not exhibit an active immune response, tumor binding of the MBCs derived from these LNs was dependent on somatic hypermutations (SHM), suggesting that they originated from a previous GC reaction. Different and overlapping types of MBC subpopulations were detected in the primary tumor and associated patient-matched LNs, some of which show clonal relationships between the two sites. Thus, our study extends our understanding of the anti-tumor memory response by revealing an inter-organ link between tumor-reactive MBC clones in ovarian cancer patients, which could potentially be manipulated in ovarian cancer patients.","dates":{"publication":"2026/05/26"},"accession":"GSE319733","cross_references":{"GSM":["GSM9524785","GSM9524774","GSM9524773","GSM9524784","GSM9524776","GSM9524787","GSM9524786","GSM9524775","GSM9524781","GSM9524780","GSM9524783","GSM9524772","GSM9524782","GSM9524771","GSM9524778","GSM9524789","GSM9524788","GSM9524777","GSM9524779","GSM9524790"],"GPL":["24676"],"GSE":["319733"],"taxon":["Homo sapiens"]}}